LIN BIOSCIENCE, INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. LBS-008
2. LBS-007
3. LBS-002
4. LBS-009
2. LBS-007
3. LBS-002
4. LBS-009
The content above was translated by Ai
Founded Year
2016
Unified Business No.
43814765
Status
Active
Number of Employees
0
Total Paid-in
Capital
835,060,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2018)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Lin BioScience, Inc. (TPEx: 6696) is a drug development company established in 2016 focusing on advancing novel therapies and first-in-class treatments for unmet medical needs in various therapeutic areas such as ophthalmology, oncology, and metabolic diseases. Lin BioScience’s pipeline currently consists of four candidate drugs. LBS-008 treating dry age-related macular degeneration and Stargardt disease, and LBS-009 treating nonalcoholic steatohepatitis are developed by its subsidiary Belite Bio Inc. (Nasdaq: BLTE). LBS-007 treating acute leukemias and solid tumors, and LBS-002 treating glioblastoma and the metastasis are developed by Lin BioScience, inc..
The content above was translated by Ai
